AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06479629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch tablet
Study NCT05517434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation
Description: Participants will undergo a bone marrow aspiration. About 10 mL of BMA will be collected from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest using the Cervos Marrow Cellution™ kit. The BMA does not require processing using a centrifuge after collection. 9 mL (or less) of BMA is injected into the osteoarthritic knee joint after collection (Arm A, Study 1).
Study NCT05517434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo Comparator for BMA)
Description: Participants will undergo a bone marrow aspiration to collect about 10 mL of BMA from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest. However, 0.9% sodium chloride (NaCl) Baxter or equivalent (9 mL) is injected into the osteoarthritic knee joint (Arm C, Study 1).
Study NCT05517434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations
Description: Participants will undergo a lipoaspiration. 40 mL of lipoaspirate (LA) will be collected from subcutaneous adipose tissue. LA will be processed using the Cervos LIPO-PRO™ kit and a centrifuge. Participants will also undergo a blood draw. About 30 mL of whole blood will be collected from the antecubital fossa. Whole blood will be processed using the Cervos KEYPRP kit and a centrifuge. After processing, 9 mL (or less) of LAM is injected first followed immediately by 2 mL (or less) of LP-PRP into the osteoarthritic knee joint (Arm B, Study 2).
Study NCT05517434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo Comparator for LAM + LP-PRP)
Description: Participants will undergo a lipoaspiration to collect 40 mL of LA and a blood draw to collect about 30 mL of whole blood. However, 0.9% of sodium chloride (NaCl) Baxter or equivalent is injected twice (9 mL + 2 mL) into the osteoarthritic knee joint (Arm D, Study 2).
Study NCT06593431 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidative Radiation
Description: Participants will receive treatment through radiation therapy
Study NCT06681220 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PARP inhibitor/Temozolomide
Description: PARP inhibitor 200mg/day +Temozolomide 40mg/day daily will be given in combination x21 days each cycle
Study NCT06681220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion x 21 days each cycle
Study NCT05037760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050 monotherapy
Description: KER-050 administered (SC) for up to 13 cycles. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
Study NCT05037760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050 in combination with ruxolitinib
Description: KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
Study NCT06267937 — intervention group
Intervention type: PROCEDURE
Intervention: Access to surgery
Description: access to surgery after hip fracture
Study NCT06267937 — intervention group
Intervention type: OTHER
Intervention: type of intitution
Description: public or private health care facility
Study NCT04605497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission \& discharge + additional 10 days during postpartum period
Study NCT04605497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Self-Capillary Blood Glucose Monitoring (SCBG)
Description: Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear
Study NCT06232850 — intervention group
Intervention type: OTHER
Intervention: Position sense and manual dexterity evaluate
Description: Position sense and manual dexterity evaluate
Study NCT04969601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine COMIRNATY® (BNT162b2)
Description: two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
Study NCT06163495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen Free Time with Friends intervention
Description: School-based extracurricular intervention focusing on time spent with friends and screen media use
Study NCT05422612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intervention C Placebo
Description: A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
Study NCT06221540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myth busting information leaflet
Description: A written patient information leaflet displaying ten food allergy myths with the myth-busting evidence-based information clearly stated, focusing on themes pertinent to the myth-busting information
Study NCT06625385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ V.A.C.® Peel and Place Dressing
Description: Application of 3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy
Study NCT05585684 — intervention group
Intervention type: OTHER
Intervention: Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection
Description: Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.
Study NCT05589363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC block with bupivacaine/liposomal bupivacaine
Description: Patients will be randomized to receive an ABC block using bupivacaine/liposomal bupivacaine solution
Study NCT05589363 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ABC block with saline
Description: Patients will be randomized to receive an ABC block using normal saline
Study NCT06624956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucose, insulin, and potassium (GIK)
Description: GIK formulation: 100 g/L glucose, 33 U/L insulin, and 40 mmol/L KCl~Reference PMID: 32151220. Formulation represents a 50% reduction in compounded solute combination from the reference study, which allows for administration via peripheral IV.
Study NCT06624956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid Infusion
Description: placebo
Study NCT06624956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crystalloid Infusion
Description: placebo
Study NCT05300139 — intervention group
Intervention type: OTHER
Intervention: Color Doppler Ultrasound
Description: Comparison between D90±5 and baseline CDUS
Study NCT06171139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling Tool
Description: Non-therapeutic educational intervention
Study NCT06171139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.
Study NCT05980091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle
Study NCT05980091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum LH, E2, P4
Description: In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels
Study NCT05980091 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol Valerate 2 MG
Description: Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)
Study NCT05980091 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Progesterone 100 Mg Vaginal Insert
Description: The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily
Study NCT05980091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum P4 day of ET
Description: On the day of embryo transfer (ET), a blood test is taken to measure serum P4
Study NCT05980091 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Embryo transfer
Description: Procedure in which embryo is transferred into the uterus
Study NCT06026345 — intervention group
Intervention type: DEVICE
Intervention: Affera Platform
Description: A cardiac ablation will be performed using the Affera Platform
Study NCT06684314 — intervention group
Intervention type: DRUG
Intervention: Efanesoctocog alfa
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
Study NCT06685718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-60366
Description: Administered orally
Study NCT05202574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous drug
Description: intravenous drug injection
Study NCT05202574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous drug
Description: intravenous drug injection
Study NCT04893629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mono nuclear cells injection
Description: trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group
Study NCT04893629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin+furosemide+captopril
Description: classical heart failure medical treatment
Study NCT05043792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT-00920
Description: TT-00920 Tablets
Study NCT05043792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TT-00920 Placebo
Description: TT-00920 Placebo Tablets
Study NCT06711198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality simulation
Description: The student will be put on the Meta Quest 3 virtual reality glasses and the episiotomy application will be started via the computer integrated with the glasses. The episiotomy application will start with the image of a woman who has given birth in the delivery room on the delivery table. The student is expected to select the appropriate materials and complete the episiotomy repair of the woman with the correct steps.
Study NCT04654130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: NFB is a type of brain training in which a person is given real-time information (or feedback) from their own brain activities to help them potentially change how their brain is functioning (i.e., to work in a healthier or more effective manner). In the current study, we will implement at-home, supervised (via teleconferencing) neurofeedback sessions using the Muse headband paired with the Myndlift software application to conduct alpha-down neurofeedback once per week, for 19 weeks.
Study NCT06072170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Single administration thirty minutes after the start of a high-fat breakfast
Study NCT05401929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
Study NCT05401929 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iTBS
Description: Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
Study NCT06072170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration thirty minutes after the start of a high-fat breakfast
Study NCT05798650 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: facial dissatisfaction
Description: Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs.
Study NCT05798650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: facial dissatisfaction
Description: Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs.
Study NCT04014712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: Oral, Single dose
Study NCT04454203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: An infiltration of mepivacaine superomedially to the femoral artery via perineural catheter.
Study NCT04454203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: An infiltration of saline superomedially to the femoral artery via perineural catheter.
Study NCT04014712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Single dose
Study NCT04454203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perifemoral Injection of Local Anesthetic
Description: Infiltration of mepivacaine superomedially to the formal artery via perineural catheter in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
Study NCT06685289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 200mg, oral, twice daily, continuous medication for 6 months
Study NCT06685289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1250mg/m2, oral, twice daily, treatment for 2 weeks with 1 week off, with 3 weeks as a treatment cycle (a total of 8 treatment cycles)
Study NCT06685289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1250mg/m2, oral, twice daily, treatment for 2 weeks with 1 week off, with 3 weeks as a treatment cycle (a total of 8 treatment cycles)
Study NCT04454203 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Perifemoral Injection of Local Anesthetic
Description: Infiltration of saline superomedially to the formal artery via perineural catheter that should NOT numb the nerves that contribute to tourniquet hypertension intraoperatively.
Study NCT06709963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITBS
Description: We will use a coil called Cool-6000 A/P to conduct real and sham control. This coil will be placed on the scalp of older adults. The iTBS protocol will begin with a 2-s burst train (totally 30 pulses), repeating every 10 s. Each burst train will consist of 10 triplet pulses with an inter-burst interval of 0.16 s, thus the triplets fire at a rate of 5 Hz. ITBS parameters will include three continuous pulses at 50 Hz repeated at 5 Hz (2s on, 8s off) for a total of 600 pulses.~We will administer two rounds of iTBS per treatment day, with a 15-minute interval between the two sessions. In total, each participant will receive 1,200 stimuli during a single-session iTBS, totaling for 14 days. Each treatment session will last for about 30 minutes. Intermittent θ-burst stimulation intensity will be set at 70% of the resting motor threshold.
Study NCT05058196 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Whole breast radiotherapy
Description: Whole breast radiotherapy after surgery
Study NCT05058196 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intra Operative Radiotherapy
Description: Intra Operative Radiotherapy
Study NCT05437666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and booklet
Description: The education program was given both an educational presentation accompanied by a physiotherapist once a week for six weeks and a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
Study NCT05437666 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Booklet
Description: The control group will be given a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
Study NCT06684847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: subcutaneous efgartigimod PH20 SC given by prefilled syringe
Study NCT06684847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC
Description: subcutaneous placebo PH20 SC given by prefilled syringe
Study NCT06691191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 mg
Description: After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
Study NCT06691191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg
Description: After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
Study NCT04878263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hospitalization
Description: Conventional care pathway : patients will be hospitalized as long as necessary and then followed according to High Health Authorities recommendations and usual practices.
Study NCT04878263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIL-EAS ic care pathway
Description: Organized care pathway with a maximum 4 working day long conventional hospitalization followed by hospitalization at home with a follow up combining hospital and private practice competences.
Study NCT06485843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OA-SYS
Description: OA-SYS is made of several types of cells obtained from fat tissue for the treatment of osteoarthritis.
Study NCT06626672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Intervention
Description: Access to a digital platform including weekly workout videos, live workouts, recipes, study summaries, and a consultation hour.
Study NCT06709963 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ITBS
Description: We will use a coil called Cool-6000 A/P to conduct real and sham control. This coil will be placed on the scalp of older adults. The iTBS protocol will begin with a 2-s burst train (totally 30 pulses), repeating every 10 s. Each burst train will consist of 10 triplet pulses with an inter-burst interval of 0.16 s, thus the triplets fire at a rate of 5 Hz. ITBS parameters will include three continuous pulses at 50 Hz repeated at 5 Hz (2s on, 8s off) for a total of 600 pulses.~We will administer two rounds of iTBS per treatment day, with a 15-minute interval between the two sessions. In total, each participant will receive 1,200 stimuli during a single-session iTBS, totaling for 14 days. Each treatment session will last for about 30 minutes. Intermittent θ-burst stimulation intensity will be set at 70% of the resting motor threshold.
Study NCT06768723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm-up (specifically, Post-Activation Performance Enhancement)
Description: Assess which intervention delivered the best acute performance enhancements.
Study NCT06768723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm-up (specifically, Post-Activation Performance Enhancement)
Description: Assess which intervention delivered the best acute performance enhancements.
Study NCT04775459 — intervention group
Intervention type: DRUG
Intervention: Surfactant administration until 2020
Description: Surfactant is administrated if Fi02 >30% among the Guidelines of 2019
Study NCT04588857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.
Study NCT04588857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.
Study NCT05804825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Argument inoculation messages
Description: Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.